Needham lowered the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $11 and keeps a Buy rating on the shares after the company previewed its FY25 results and gave guidance for 2026. Following the company’s pre-announcement, the firm is adjusting its FY26 Aucatzyl sales estimate to $133M from $167M to reflect the provided guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL: